Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 18. https://www.oncotarget.com/archive/v12/i18/ Priority Research Paper (Cover) - “Normal tissue and tumor microenvironment adaptations to aerobic exercise enhance doxorubicin anti-tumor efficacy and ameliorate its cardiotoxicity in retired breeder mice” https://doi.org/10.18632/oncotarget.28057 Research Paper - “Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor...
Sep 01, 2021•9 min
Oncotarget published "Carcinoma cells that have undergone an epithelial-mesenchymal transition differentiate into endothelial cells and contribute to tumor growth" which reported that the authors investigated whether EMT can confer endothelial attributes upon carcinoma cells, augmenting tumor growth and vascularization. Hypoxic regions, demarcated by HIF-1α staining, exhibited focal areas of E-cadherin loss and elevated levels of vimentin and the EMT-mediator FOXC2. Implantation of MCF-7 cells, ...
Sep 01, 2021•16 min
Lantern Pharma (a pharmaceutical company developing targeted cancer therapies) created a new drug candidate and next generation member of the acylfulvene class of prodrugs, named LP-184. Researchers from Lantern Pharma and REPROCELL (a commercial contract research organization) conducted a study to test the anti-tumor activity of this preclinical compound in a variety of NSCLC cell lines. In 2021, Oncotarget published the research paper the team authored, entitled, “The acylfulvene alkylating ag...
Sep 01, 2021•5 min
In 2019, a study published in Oncotarget showed a C. elegans cancer screening test could detect pancreatic tumors in mice. In 2021, a team of researchers from Osaka University and Hirotsu Bio Science Inc. sought to employ this clinical tactic in the context of early pancreatic cancer detection in humans. Their paper was published as the cover of Oncotarget’s Volume 12, Issue, 17, and entitled, “Scent test using Caenorhabditis elegans to screen for early-stage pancreatic cancer.” “Pancreatic duct...
Aug 19, 2021•8 min
Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 17. https://www.oncotarget.com/archive/v12/i17/ Research Paper (Cover) - “Scent test using Caenorhabditis elegans to screen for early-stage pancreatic cancer” https://doi.org/10.18632/oncotarget.28035 Research Paper - “The role of circulating miRNAs and CA19-9 in pancreatic cancer diagnosis” https://doi.org/10.18632/oncotarget.28038 Research Paper - “Diverse transcriptional regulation an...
Aug 18, 2021•8 min
Oncotarget published this trending research perspective on June 22, 2021, entitled, "Association of high-sensitivity C-reactive protein and odds of breast cancer by molecular subtype: analysis of the MEND study" by researchers from Duke University, Durham, NC; University of Lagos, Lagos State, Nigeria; Obafemi Awolowo University Teaching Hospital, Ile-Ife, Osun State, Nigeria; University College Hospital, University of Ibadan, Ibadan, Oyo State, Nigeria; Federal Medical Center, Abeokuta, Ogun St...
Aug 16, 2021•6 min
Oncotarget published "The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations" which reported that KEAP1 mutant NSCLCs further activate NRF2 and upregulate its client PTGR1. LP-184, a novel alkylating agent belonging to the acylfulvene class is a prodrug dependent upon PTGR1. The authors hypothesized that NSCLC with KEAP1 mutations would continue to remain sensitive to LP-184. LP-184 demonstrated highly pot...
Aug 10, 2021•15 min
Oncotarget’s cover paper this week (Volume 12, Issue 16) is entitled, "Epigenetic signatures differentiate uterine and soft tissue leiomyosarcoma," by researchers from Yale University School of Medicine, New Haven, CT. “In this study, we performed a comprehensive analysis and compared the DNA methylation and RNA expression profiles of ULMS and STLMS samples from the TCGA-SARC study.” First, the team identified two LMS subtypes based on their site of origin: uterine LMS (ULMS) and non-uterine sof...
Aug 05, 2021•6 min
Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 16. https://www.oncotarget.com/archive/v12/i16/ Cover Paper - “Epigenetic signatures differentiate uterine and soft tissue leiomyosarcoma” https://doi.org/10.18632/oncotarget.28032 Research Paper - “High CD39 expression is associated with the non-muscle-invasive phenotype of human bladder cancer” https://doi.org/10.18632/oncotarget.28029 Research Paper - “MiR-7-5p inhibits thyroid cell p...
Aug 04, 2021•7 min
The Ride for Roswell is one of the nation’s largest cycling events—hosted by Roswell Park Comprehensive Cancer Center—with ambitious goals to raise awareness and funds for cancer research and patient care. This charity bike ride, based out of Buffalo, New York, has brought people together for 25 years to celebrate cancer survivors, pay tribute to lives that have been lost, and to work together to support research and find a cure. When it opened its doors in Buffalo in 1898, Roswell Park Comprehe...
Jul 28, 2021•5 min
Biomarkers are any measurement in the body that can indicate disease, infection, or effects of the environment. These indicators are commonly used to reveal disease, but they can also be used to support personalized cancer therapy. “In recent years, there has been an increased focus on personalized cancer therapy. One important aspect is the identification of key biomarkers that support a given treatment plan.” Multiple biomarkers have been identified in breast cancers as helpful tools to guid...
Jul 28, 2021•5 min
Oncotarget published "A novel E2F1-regulated lncRNA, LAPAS1, is required for S phase progression and cell proliferation" which reported that long non-coding RNAs are major regulators of many cellular processes, including cell cycle progression and cell proliferation. Inhibition of LAPAS1 expression increases the percentage of S phase cells, and its silencing in synchronized cells delays their progression through S phase. In agreement with its suggested role in cell cycle progression, prolonged i...
Jul 26, 2021•3 min
Oncotarget’s cover paper this week (Volume 12, Issue 15) is entitled, "Terpyridine platinum compounds induce telomere dysfunction and chromosome instability in cancer cells." About the Study: Researchers from the National Institutes of Health, University Paris-Saclay, Kazusa DNA Research Institute, and the University of Edinburgh used a dual-Human Artificial Chromosome (HAC) assay to analyze the genomic activity of six telomere-targeting platinum compounds. The dual-HAC assay was previously crea...
Jul 22, 2021•5 min
Listen to summaries of the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 15. https://www.oncotarget.com/archive/v12/i15/ Cover Paper - “Terpyridine platinum compounds induce telomere dysfunction and chromosome instability in cancer cells” https://doi.org/10.18632/oncotarget.28020 Research Paper - “RNA expression differences in prostate tumors and tumor-adjacent stroma between Black and White Americans” https://doi.org/10.18632/oncotarget.28024 Re...
Jul 21, 2021•9 min
Oncotarget published this trending research paper on May 1, 2018, entitled, "Treatment of ovarian cancer by targeting the tumor stem cell-associated carbohydrate antigen, Sialyl-Thomsen-nouveau" by researchers from the Massachusetts General Hospital, Boston, MA; Siamab Therapeutics, Inc., Newton, MA; Harvard Medical School, Boston, MA. Abstract: Recurrent ovarian cancer (OvCa) is thought to result in part from the inability to eliminate rare quiescent cancer stem cells (CSCs) that survive cytoto...
Jul 16, 2021•5 min
Oncotarget has started a new venture to expand our reach and connect with other relevant platforms using TrendMD. The TrendMD widget has been applied at the bottom of all research papers on Oncotarget.com to serve recommended content to our readers, and readers on thousands of other high-traffic websites and scholarly platforms. Recommended content is based on the content currently being viewed, content that has been viewed in the past, and content other similar readers are viewing. “[TrendMD’s]...
Jul 15, 2021•3 min
This week's cover paper of Oncotarget (Volume 12, Issue 14) is entitled, "Esomeprazole enhances the effect of ionizing radiation to improve tumor control," by researchers from Baylor College of Medicine, University of Texas MD Anderson Cancer Center, and Texas Children’s Hospital. Abstract: The resistance of cancer cells to radiation-based treatment is a major clinical challenge confounding standard of care in cancer. This problem is particularly notable in many solid tumors where cancer cells a...
Jul 08, 2021•4 min
Listen to short summaries of the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 14. https://www.oncotarget.com/archive/v12/i14/ Cover Paper - “Esomeprazole enhances the effect of ionizing radiation to improve tumor control” https://doi.org/10.18632/oncotarget.28008 Research Paper - “Mebendazole disrupts stromal desmoplasia and tumorigenesis in two models of pancreatic cancer” https://doi.org/10.18632/oncotarget.28014 Research Paper - “MRI texture ...
Jul 06, 2021•8 min
Oncotarget published "TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic" which reported normal fibroblasts do not undergo apoptosis following rhTRAIL plus ONC201. In vivo, MDA-MB-361 tumor growth rate is significantly reduced following treatment with a combination of ONC201 and rhTRAIL as compared to control tumors. Natural killer cells which use TRAIL to kill DR5-expressing cancer cells, exhibit greater cytotoxicity against ONC201...
Jul 06, 2021•35 min
Oncotarget published this trending research paper on October 20, 2020, entitled, "TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic" by researchers from Temple University, Philadelphia, PA; Fox Chase Cancer Center, Philadelphia, PA; Brown University, Providence, RI; Brown University and the Lifespan Health System, Providence, RI. Abstract: ONC201 was initially identified as an inducer of cell death through the tumor necrosis factor...
Jul 02, 2021•6 min
This week's cover paper of Oncotarget (Volume 12, Issue 13) is entitled, "Oncogenic transformation of NIH/3T3 cells by the overexpression of L-type amino acid transporter 1, a promising anti-cancer target," by researchers from Kindai University, Higashiosaka-Shi, Osaka, Japan; Tohoku University, Sendai-Shi, Miyagi, Japan; Tokyo University of Science, Noda-shi, Chiba, Japan; Hyogo University of Health Sciences, Kobe-Shi, Hyogo, Japan. Abstract: L-type amino acid transporter 1 (LAT1)/SLC7A5 is the...
Jun 24, 2021•6 min
Listen to short summaries of the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 13. https://www.oncotarget.com/archive/v12/i13/ Cover Paper “Oncogenic transformation of NIH/3T3 cells by the overexpression of L-type amino acid transporter 1, a promising anti-cancer target” https://doi.org/10.18632/oncotarget.27981 News “A new class of radiosensitizers for glioblastoma” https://doi.org/10.18632/oncotarget.27970 (PDF Download) Research Paper “A platf...
Jun 23, 2021•9 min
Oncotarget published this trending research paper on March 30, 2021, entitled, "Inhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine" by researchers from the University of Texas MD Anderson Cancer Center, Houston, Texas. Triple-negative breast cancer (TNBC) accounts for 10-15% of all breast cancers. “Triple-negative” refers to the lack of HER2 protein and estrogen and progesterone receptors. This means that TNBC cannot be treated with hormo...
Jun 18, 2021•6 min
In this week's cover paper of Oncotarget (Volume 12, Issue 12), entitled, "Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity," researchers used the CRISPR-Cas9 tool to analyze a p53 mutation in triple-negative breast cancer. The researchers from the City University of New York, Columbia University, and Weill Cornell Medical College wrote that both the C-terminal domain (CTD) and oligom...
Jun 10, 2021•7 min
Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 12. The full issue of Oncotarget: https://www.oncotarget.com/archive/v12/i12/ COVER PAPER: “Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity” https://doi.org/10.18632/oncotarget.27975 NEWS: “LY6 gene family presents a novel class of potential biomarkers associated with overall...
Jun 09, 2021•6 min
Oncotarget published this trending research paper on April 13, 2021, entitled, "Urine protein biomarkers of bladder cancer arising from 16-plex antibody-based screens" conducted by researchers from the University of Houston and UT Southwestern Medical Center. Bladder cancer is four times more common among men than women, and it is the sixth most common cancer diagnosis in the United States. However, researchers have found that cystoscopy—the primary method physicians use to diagnose patients wit...
Jun 04, 2021•5 min
In this week's cover paper of Oncotarget (Volume 12, Issue 11) entitled, "CEA as a blood-based biomarker in anal cancer," researchers from The University of Texas – MD Anderson Cancer Center, Terasaki Foundation of Biomedical Sciences, and Vanderbilt Ingram Cancer Center conducted a retrospective, single-institution study to determine the correlation between carcinoembryonic antigen (CEA) levels (a commonly employed assay for patients with colorectal adenocarcinoma) and biopsy-proven Squamous ce...
May 27, 2021•6 min
Listen to the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 11. View the complete issue: https://www.oncotarget.com/archive/v12/i11/ COVER PAPER: “CEA as a blood-based biomarker in anal cancer” https://doi.org/10.18632/oncotarget.27959 NEWS: “FGFR1, a novel biomarker for metastatic castration-resistant prostate cancer?” https://doi.org/10.18632/oncotarget.27957 (PDF Download) EDITORIAL: “Advances in innovative exosome-technology for real time mon...
May 26, 2021•8 min
Skin cancer is a highly preventable cancer (in non-hereditary cases), due to a major risk factor being prolonged exposure to ultraviolet (UV) radiation. However, skin cancer is the most commonly diagnosed cancer in the United States. By the age of 70, one in five Americans are predicted to be diagnosed with skin cancer. There are three types of cells that are usually involved in skin cancer: basal cells, squamous cells, and melanocytes (or pigment producing cells). The type of skin cell affected...
May 21, 2021•3 min
Oncotarget published this trending research paper on June 4, 2019, entitled, “Dissecting the role of RNA modification regulatory proteins in melanoma,” by researchers from the Department of Pathology, Yale University School of Medicine, and the Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham. “Since RNA is a key molecule that drives every cellular process, their deregulation is present in nearly all human disease and play a causative role.” The researchers ...
May 21, 2021•5 min
